Datopotamab Deruxtecan

26 trials 11 recruiting

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

11 Recruiting

12 Completed trials

5 Sponsors

18 Countries

Phase III

Phase II

Phase III: 13 Phase II/III: 1 Phase II: 7 Phase I/II: 1 Phase I (Other): 2 Phase I (FiH): 2

Oversight events:

1 serious breach 17 temporary halts 1 urgent safety measure across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 7 Triple negative breast cancer 4 Non-small cell lung cancer stage III 1 Prostate cancer 1 Bladder cancer 1 Metastatic glioma 1 Non-small cell lung cancer stage II 1 Ovarian cancer 1 Metastases to biliary tract 1 Non-small cell lung cancer stage IIIB 1 Hormone refractory breast cancer 1 Non-small cell lung cancer stage I 1

Sponsors using this IMP

AstraZeneca AB 17 Daiichi Sankyo Inc. 6 Medica Scientia Innovation Research S.L. 1 Medical University Of Vienna 1 Queen Mary University Of London 1

All trials — page 2

26 total

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Halted

2024-516916-93-00 Phase I (Other) 3 countries Daiichi Sankyo Inc.
Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations Ended

2024-511449-21-00 Phase II 3 countries Daiichi Sankyo Inc.

Showing 25–26 of 26 trials

← All drugs A–Z